Drug discovery at the site of pulmonary tuberculosis
The protracted duration of standard tuberculosis (TB) therapy suggests the inadequacy of current first line TB drugs to eliminate the causative agent Mycobacterium tuberculosis (Mtb). Among multiple potential causes, this may be due to poor distribution of TB drugs into the pulmonary lesions in whic...
Main Author: | Tanner, Lloyd |
---|---|
Other Authors: | Wiesner, Lubbe |
Format: | Doctoral Thesis |
Language: | English |
Published: |
Faculty of Health Sciences
2019
|
Online Access: | http://hdl.handle.net/11427/30068 |
Similar Items
-
Tuberculosis drug discovery in the CRISPR era.
by: Jeremy Rock
Published: (2019-09-01) -
Tuberculosis Drug Discovery and Development 2019
Published: (2020) -
Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
by: Diana Machado, et al.
Published: (2018-07-01) -
New approaches to filling the gap in tuberculosis drug discovery.
by: Martina Casenghi, et al.
Published: (2007-11-01) -
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
by: Aaron Goff, et al.
Published: (2020-07-01)